In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alseres Pharmaceuticals Inc.

Latest From Alseres Pharmaceuticals Inc.

Amakem's rock inhibitor rolling towards the market

Belgian biotech company Amakem has begun a proof-of-concept study with its lead product, the rho kinase (ROCK) inhibitor AMA0076, in glaucoma and ocular hypertension, after raising €18 million last year in a series A financing. The product is designed to avoid the risk of systemic and local side-effects such as hyperaemia that have caused problems for other products in this class, and uses the company's Localized Drug Action platform.

Metabolic Disorders Cardiovascular

Deals Shaping The Medical Industry (03/2012)

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Radiopharm Specialist Navidea Steps Up Licensing Activity, Opens Boston Office In Anticipation Of Key Approval Decision

In the past year, Navidea has struck two licensing deals, expanded its geographic footprint, filed for its lead candidate Lymphoseek in the U.S. and has plans to file in Europe, and refocused into a commercial-ready biopharma specializing in radiopharmaceutical diagnostic products.

Business Strategies Clinical Trials

Top Partnering Opportunities In Neuroscience: The Ugly Truth

Consultant notes some promising candidates in a challenging space for investment.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Molecular Imaging
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Boston Life Sciences Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alseres Pharmaceuticals Inc.
  • Senior Management
  • Peter G Savas, CEO
    Kenneth L Rice, EVP, Fin. & Admin. and CFO
  • Contact Info
  • Alseres Pharmaceuticals Inc.
    Phone: (508) 497-2360
    239 South St.
    Hopkinton, MA 01748